Ibrance can be used regardless of underlying condition in BC

By | translator Alice Kang

21.12.22 18:24:03

가나다라 0

PFS of breast cancer patients improved greatly with the introduction of the trusted Ibrance

Shows stable effect in patients regardless of underlying preexisting condition… may be maintained over 40 months

“A real-world study on Koreans in plan… the role of CDK4/6 inhibitors will continue to expand"

It has been 5 years since Pfizer’s breast cancer treatment ‘Ibrance (Palbociclib)’ was introduced to the Korean market. As the first cyclin-dependent kinase 4/6 (CDF 4/6) inhibitor, the drug had innovated the treatment paradigm for patients with metastatic and recurrent hormone receptor-positive (HR-positive) and human epidermal growth factor receptor 2-negative (HER2-negative) breast cancer.

With 5 years' worth of accumulated data, Ibrance has settled in as a trusted and reliable drug for doctors. In particular, Ibrance is considered the ‘go-to drug’ for those who have underlying conditions or have side effect concerns. At a meeting with Dailypharm, Kyong-Hwa Park, Professor of Oncology and Hemat

(same@dailypharm.com)

If you want to see the full article, please JOIN US (click)